Alnapharm
Alnapharm
Alnapharm
Alnapharm
Alnapharm
Alnapharm

Dermatology

Psoriasis

Psoriasis is a chronic, incurable dermatological disease. The prevalence of psoriasis is 1.5 to 2% of the population in the industrialized nations. About 80% of the patients suffer from psoriasis vulgaris. Psoriasis vulgaris (psoriasis) represents a frequent and usually chronically progressing dermatological disease. Psoriasis is incurable hence, a permanent treatment is necessary.

Most of the patients use cream products to treat their Psoriasis affected skin. In addition to treatment, patients use individual skin care products to maintain the skin and keep it smooth. These additional costs for individual care products differs in price and causes a high financial burden. Alnapharm is currently developing the skin crème for the treatment of Psoriasis.

Products

The first healthcare product of Alnapharm is the dietary supplement OSVALIN®. OSVALIN® is a unique silicon preparation containing hydrolyzed, colloidal silicon dioxide in the highest possible concentration.

more >>

Responsibility

We want to take responsibility for each project that we are launching and with the specific task that goes with it. We are aware of the importance of our projects, with which we enter into an obligation to use our work for the highest good of the patient.

more >>

Research and Development

As man is a complex creature itself, we derive our knowledge of the complexity of the plants, the active ingredients that nature gives us. We strive to receive our developments from what already exists.

more >>

Newsroom

Stay informed about our newest inovations and achievments

more >>